Andre Goy, MD
Promising clinical trial data have highlighted advances in the treatment of mantle cell lymphoma (MCL), but an important next step is applying this progress to routine clinical practice, said Andre Goy, MD.
at the 2018 Pan Pacific Lymphoma Conference, Goy, chief of the Division of Lymphoma, and chairman and director of John Theurer Cancer Center, shared insight on the new array of treatment options for MCL and how to properly implement them.
OncLive: Please provide an overview of your presentation on MCL.
: I am here to share my perspective on MCL and some of the progress we have made. Importantly, we have made significant progress. However, there is a disconnect with what we've seen in clinical trials and in the real world. Overall, in clinical trials, there's been a great endeavor of pushing research in MCL because the outcome with standard therapy is very dismal. If we look at the progression of the last 3 decades in clinical trials of MCL, the median OS went from 2.5 years, or something like that, to 12 or 13 years. Therefore, there has definitely been progress on that front.
We also have some potential for patients to be cured, especially those who are MRD negative in the context of younger patients. Rituximab has had tremendous impact in terms of PFS and OS. Where the field is going is trying to optimize treatment by looking at different phases and trying to improve outcomes that way. This is important because although we've seen great progress in these trials, there's a disconnect. Median OS in the real world is still about 3 to 5 years.
One thing that's been identified is that for patients in their mid-to-late 60s, we can use maintenance therapy, particularly rituximab. Maintenance is now standard of care. The question that remains is what to do beyond that. In a relapsed setting, there are a number of different therapies—5 are approved.
The questions that remain are, “How long do you give maintenance therapy? Can you build up on the maintenance with rituximab? How often you need to monitor these patients? Can we do something preemptively to prevent the patient from clinically progressing?” That's what the Nordic trial showed. The median time to molecular CR was about 55 months. About 90% of patients went back on rituximab. We need to do more than just rituximab as a maintenance therapy.
Overall, we have a very changing landscape in MCL. The last aspect that is important to note is that clinical trials don't necessarily represent reality. However, we can still take the information we get and understand the disease better. I'm optimistic for what is on the horizon.
Does CAR T-cell therapy have potential in the treatment of patients with MCL?
There has been a lot of talk about CAR T cells and there's a lot of excitement. There have been some approvals in other lymphomas; commercial use is now available. We are now following the activity of these agents in patients with MCL. There are a handful of patients we are looking at this on a phase II trial. We are looking at some of the early data right now with ibrutinib.
We are seeing some high responses and exciting data, but it's too early to get into right now. This is something that will be appealing, though. One of the biggest challenges in MCL is that it is chemotherapy resistant over time. Some patients cannot be pulled back into remission with standard therapy.
There have been some exciting data with venetoclax. What are your thoughts?
Venetoclax has shown dramatic activity in early studies as a single agent in MCL. It's been very impressive, even in patients who did not respond to ibrutinib (Imbruvica). What is interesting is the combination setting. This will translate into better results in the fourth-line setting for these patients, and it's purely a nonchemotherapy option.
Is there anything else in the early stages that you are particularly excited about?
As I alluded to before, ibrutinib is a form of immunotherapy that is used in combination with a targeted therapy in MCL. There was a trial presented recently that showed patients who were heavily pretreated had a CR rate of 71%. There was another study of exactly the same design that showed a very high response rate, even in those with poor genetic risk factors. This is a good example of what immunotherapy can do. There is a lot of opportunity with anti-CD47 and other forms of immunotherapy that might provide opportunity.
What is the takeaway message you would like community oncologists to leave with?
We have made a lot of progress, thanks to clinical trials. I want more people to participate in trials. This is a really bright time in the future of MCL; this is a big step towards a cure.
- Hilal T, Wang Z, Almader-Douglas D, et al. Rituximab maintenance for mantle cell lymphoma: a meta-analysis. J Clin Oncol. 2018;36 (suppl; abstr e19557).
- Eyre T, Walter H, Iyenger S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibition therapy. In: Proceedings from the 2018 EHA Congress; June 14-17, 2018; Stockholm, Sweden. Abstract S855.